Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 8, 2026, 8:15 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 195 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: HAART Clear all
Completed Phase 4 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Adding Enfuvirtide to Oral Highly Active Antiretroviral Therapy (HAART) in Human Immunodeficiency Virus (HIV) Patients With Prior Treatment Experience

NCT00487188
View directory record Official record
Conditions
HIV Infections
Interventions
Enfuvirtide, Highly active antiretroviral treatment (HAART)
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
3
States / cities
Cleveland, Ohio • Austin, Texas • Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2015 · Synced Sep 8, 2026, 8:15 AM EDT
Terminated Phase 1 Interventional

Study Evaluating Vaccine in Adults With HIV

NCT00195312
View directory record Official record
Conditions
HIV Infections
Interventions
HIV-1 gag DNA (formulated with bupivacaine), IL-15 DNA (formulated with bupivacaine), IL-12 DNA (formulated with bupivacaine), Sodium chloride injection USP (0.9%)
Biological
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2007
U.S. locations
6
States / cities
Birmingham, Alabama • Denver, Colorado • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 4, 2007 · Synced Sep 8, 2026, 8:15 AM EDT
Completed No phase listed Observational

Observational Study of Treated and Untreated Acute and Early HIV-1 Infection

NCT00219934
View directory record Official record
Conditions
HIV Infections
Interventions
Antiretroviral therapy
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
16 Years and older
Enrollment
399 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 16, 2012 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Not applicable Interventional

A Study of Thalidomide in HIV-Infected Patients Who Are Receiving HAART

NCT00002392
View directory record Official record
Conditions
HIV Infections
Interventions
Thalidomide
Drug
Lead sponsor
Rockefeller University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Phase 2 Interventional

The Role of Ampligen in Strategic Therapeutic Intervention (STI) of HAART

NCT00035893
View directory record Official record
Conditions
HIV Seropositivity, HIV Infection
Interventions
poly I-poly C12U
Drug
Lead sponsor
AIM ImmunoTech Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2006
U.S. locations
10
States / cities
Fountain Valley, California • Los Angeles, California • Norwalk, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 16, 2013 · Synced Sep 8, 2026, 8:15 AM EDT
Completed No phase listed Observational

Central Nervous System Disease in HIV-infected Children on HAART

NCT00110331
View directory record Official record
Conditions
HIV Infections, Central Nervous System Diseases
Interventions
Not listed
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
Not listed
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 11, 2019 · Synced Sep 8, 2026, 8:15 AM EDT
Completed No phase listed Observational

HIV Resistance and Treatment Strategies

NCT00581802
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated May 3, 2012 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Phase 4 Interventional

4-Day-A-Week Treatment Plan for HIV Infected Adolescents

NCT00068809
View directory record Official record
Conditions
HIV Infections
Interventions
Short Cycle Antiretroviral Therapy
Procedure
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
12 Years to 24 Years
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
8
States / cities
Los Angeles, California • San Diego, California • Washington D.C., District of Columbia + 5 more
Source: ClinicalTrials.gov public record
Updated Feb 28, 2017 · Synced Sep 8, 2026, 8:15 AM EDT
Completed No phase listed Observational

HIV Expression in Patients With Low Viral Load on Highly Active Antiretroviral Therapy (HAART)

NCT00043641
View directory record Official record
Conditions
HIV Infections
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2013
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Oct 20, 2019 · Synced Sep 8, 2026, 8:15 AM EDT
Withdrawn Phase 2 Interventional

Effect of HAART Vs. Statin Treatment on Endothelial Function and Inflammation/Coagulation

NCT01515813
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Pravastatin sodium, Efavirenz/Emtricitabine/Tenofovir Disoproxil Fumarate
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
9
States / cities
Los Angeles, California • Torrance, California • St Louis, Missouri + 6 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2016 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Not applicable Interventional Results available

Short-term Disulfiram Administration to Accelerate the Decay of the HIV Reservoir in Antiretroviral-treated HIV Infected Individuals

NCT01286259
View directory record Official record
Conditions
HIV-1 Infection
Interventions
Disulfiram
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
San Francisco, California • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 29, 2020 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional

Safety and Efficacy of BAY 50-4798 in Patients With HIV Infection

NCT00059462
View directory record Official record
Conditions
HIV Infections
Interventions
Interleukin-2 SA, HAART
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2005
U.S. locations
9
States / cities
Birmingham, Alabama • Davis, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Dec 22, 2014 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Medication Adherence in Human Immunodeficiency Virus (HIV)

NCT02119390
View directory record Official record
Conditions
Human Immunodeficiency Virus
Interventions
Staff-delivered intervention sessions, Demographic Questionnaire, Questionnaires
Behavioral · Other
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
13 Years to 24 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Aug 1, 2016 · Synced Sep 8, 2026, 8:15 AM EDT
Completed No phase listed Observational

Determining the Barriers and Motivations to Clinical Trial Participation

NCT01937091
View directory record Official record
Conditions
HIV
Interventions
Not listed
Lead sponsor
University of North Carolina, Chapel Hill
Other
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 11, 2015 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Phase 3 Interventional Results available

Comparative Study of Three NNRTI-Sparing HAART Regimens

NCT00811954
View directory record Official record
Conditions
HIV Infection
Interventions
Emtricitabine/tenofovir disoproxil fumarate, Raltegravir, Darunavir, Ritonavir, Atazanavir
Drug
Lead sponsor
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections
Network
Eligibility
18 Years and older
Enrollment
1,814 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
55
States / cities
Birmingham, Alabama • Long Beach, California • Los Angeles, California + 39 more
Source: ClinicalTrials.gov public record
Updated Sep 4, 2014 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Not applicable Interventional

The Effects of Anti-HIV Therapy on the Immune Systems of Children and Young Adults Infected With HIV

NCT00004735
View directory record Official record
Conditions
HIV Infections
Interventions
Tetanus toxoid, Hepatitis A Vaccine (Inactivated)
Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years to 24 Years
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2000 – 2006
U.S. locations
25
States / cities
Birmingham, Alabama • Alhambra, California • Long Beach, California + 18 more
Source: ClinicalTrials.gov public record
Updated Oct 6, 2013 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Immune Activation and Drug Absorption in HIV-Infected Patients

NCT01845298
View directory record Official record
Conditions
HIV Infection
Interventions
Rifampicin 600 mg
Drug
Lead sponsor
Drexel University
Other
Eligibility
21 Years to 45 Years
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 2, 2017 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Phase 2 Interventional Results available

Safety of EVG+RTV Administered With Other Antiretroviral Agents for the Treatment of HIV-1 Infection

NCT00445146
View directory record Official record
Conditions
HIV Infections
Interventions
EVG, RTV, ARV regimen
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
Not listed
Enrollment
192 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2015
U.S. locations
47
States / cities
Pheonix, Arizona • Little Rock, Arkansas • Beverly Hills, California + 44 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2016 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Phase 3 Interventional

A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen

NCT00135395
View directory record Official record
Conditions
HIV Infections
Interventions
Atazanavir+ritonavir, Lopinavir+ritonavir
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2006
U.S. locations
52
States / cities
Hobson City, Alabama • Montgomery, Alabama • Phoenix, Arizona + 49 more
Source: ClinicalTrials.gov public record
Updated Feb 4, 2010 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Not applicable Interventional

Long-Term Assessment for Metabolic, Cardiovascular and Neurologic Problems in HIV-Infected Patients With Increased CD4 Cells Counts Following Anti-HIV Therapy

NCT00000883
View directory record Official record
Conditions
Mycobacterium Avium-intracellulare Infection, HIV Infections
Interventions
Azithromycin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
636 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1997 – 2007
U.S. locations
51
States / cities
Birmingham, Alabama • Los Angeles, California • Menlo Park, California + 31 more
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Sep 8, 2026, 8:15 AM EDT
Completed No phase listed Observational

A Study of Health-Related Quality of Life in HIV-Infected Patients Undergoing Structured Treatment Interruptions of Highly Active Antiretroviral Therapy

NCT00001948
View directory record Official record
Conditions
HIV Infection
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
Not listed
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1999 – 2002
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2008 · Synced Sep 8, 2026, 8:15 AM EDT
Completed No phase listed Observational

A Study to Evaluate the Effects of Anti-HIV Drugs in HIV-Positive Patients Who Also Have Hepatitis C Infection

NCT00001117
View directory record Official record
Conditions
HIV Infections, Hepatitis C
Interventions
Not listed
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
42
States / cities
Los Angeles, California • Menlo Park, California • San Diego, California + 27 more
Source: ClinicalTrials.gov public record
Updated Jul 31, 2008 · Synced Sep 8, 2026, 8:15 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Dose Escalation Study of Cyclophosphamide in HIV-Infected Subjects on HAART Receiving SB-728-T

NCT01543152
View directory record Official record
Conditions
HIV
Interventions
SB-728-T
Genetic
Lead sponsor
Sangamo Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
10
States / cities
Los Angeles, California • San Francisco, California • Norwalk, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated May 23, 2021 · Synced Sep 8, 2026, 8:15 AM EDT
Terminated Phase 2 Interventional

Study on Interleukin-7 (CYT107) in HIV Patients

NCT01190111
View directory record Official record
Conditions
HIV
Interventions
Interleukin-7
Biological
Lead sponsor
Cytheris SA
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2013
U.S. locations
3
States / cities
Miami, Florida • Bethesda, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 31, 2013 · Synced Sep 8, 2026, 8:15 AM EDT